PUBLISHER: Allied Market Research | PRODUCT CODE: 1365835
PUBLISHER: Allied Market Research | PRODUCT CODE: 1365835
The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research
Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.
Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.
In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.
Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.
On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.
However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.
The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.
On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)